Original Articles

Defining Benchmark Outcomes for Distal Pancreatectomy

Results of a French Multicentric Study

Durin, Thibault MD*; Marchese, Ugo MD†; Sauvanet, Alain MD, PhD‡; Dokmak, Safi MD‡; Cherkaoui, Zineb MD‡; Fuks, David MD, PhD†; Laurent, Christophe MD, PhD§; AndrĂ©, Marie MD∥; Ayav, Ahmet MD, PhD∥; Magallon, Cloe MD¶; Turrini, Olivier MD, PhD¶; Sulpice, Laurent MD, PhD#; Robin, Fabien MD, PhD#; Bachellier, Philippe MD, PhD**; Addeo, Pietro MD, PhD**; Souche, François-RĂ©gis MD, PhD††; Bardol, Thomas MD††; Perinel, Julie MD, PhD‡‡; Adham, Mustapha MD, PhD‡‡; Tzedakis, Stylianos MD†; Birnbaum, David J. MD, PhD§§; Facy, Olivier MD, PhD∥∥; Gagniere, Johan MD, PhD¶¶; Gaujoux, SĂ©bastien MD, PhD##; Tribillon, Ecoline MD***; Roussel, Edouard MD†††; Schwarz, Lilian MD, PhD†††; Barbier, Louise MD, PhD‡‡‡; Doussot, Alexandre MD, PhD§§§; Regenet, Nicolas MD∥∥∥; Iannelli, Antonio MD, PhD¶¶¶; Regimbeau, Jean-Marc MD, PhD###; Piessen, Guillaume MD, PhD****; Lenne, Xavier Msc††††; Truant, StĂ©phanie MD, PhD*; El Amrani, Mehdi MD, PhD*

Author Information
Annals of Surgery 278(1):p 103-109, July 2023. | DOI: 10.1097/SLA.0000000000005539

Abstract

Objective: 

Defining robust and standardized outcome references for distal pancreatectomy (DP) by using Benchmark analysis.

Background: 

Outcomes after DP are recorded in medium or small-sized studies without standardized analysis. Therefore, the best results remain uncertain.

Methods: 

This multicenter study included all patients undergoing DP for resectable benign or malignant tumors in 21 French expert centers in pancreas surgery from 2014 to 2018. A low-risk cohort defined by no significant comorbidities was analyzed to establish 18 outcome benchmarks for DP. These values were tested in high risk, minimally invasive and benign tumor cohorts.

Results: 

A total of 1188 patients were identified and 749 low-risk patients were screened to establish Benchmark cut-offs. Therefore, Benchmark rate for mini-invasive approach was ≥36.8%. Benchmark cut-offs for postoperative mortality, major morbidity grade ≥3a and clinically significant pancreatic fistula rates were 0%, ≤27%, and ≤28%, respectively. The benchmark rate for readmission was ≤16%. For patients with pancreatic adenocarcinoma, cut-offs were ≥75%, ≥69.5%, and ≥66% for free resection margins (R0), 1-year disease-free survival and 3-year overall survival, respectively. The rate of mini-invasive approach in high-risk cohort was lower than the Benchmark cut-off (34.1% vs ≥36.8%). All Benchmark cut-offs were respected for benign tumor group. The proportion of benchmark cases was correlated to outcomes of DP. Centers with a majority of low-risk patients had worse results than those operating complex cases.

Conclusion: 

This large-scale study is the first benchmark analysis of DP outcomes and provides robust and standardized data. This may allow for comparisons between surgeons, centers, studies, and surgical techniques.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid